Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Patients who have received prior treatment with a Lenalidomide based regimen

Next Previous
Trial Profile

A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Patients who have received prior treatment with a Lenalidomide based regimen

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Daratumumab/hyaluronidase (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms DARIA

Most Recent Events

  • 15 Jun 2023 Final outcomes assessing the efficacy/safety of the Dara-Ixa-dex combination assecond-line therapy in pts with RRMM previously treated with a len-based regimen presented at the 28th Congress of the European Haematology Association.
  • 05 Jun 2022 Status changed from recruiting to completed.
  • 14 Dec 2021 Results assessing the efficacy of daratumumab in combination with ixazomib and dexamethasone (Dara-Ixa-dex) as second-line therapy in pts with RRMM who have been previously treated with a lenalidomide-based regimen, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top